ESMO 2023: TROPION-Breast01 And -Lung01 Studies Breathe Life Into Dato-DXd

 
• By Alexandra Shimmings

The future for AstraZeneca/Daiichi Sankyo’s TROP2-targeted ADC candidate Dato-DXd is looking more positive after details of their TROPION-Lung01 and TROPION-Breast01 Phase III studies were presented at ESMO.    

AZ Cambridge campus 2021

More from Clinical Trials

More from R&D